Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report

Mona Klara Ros Müller; Monika Christ; Markus Naumann; Antonios Bayas

doi:10.1177/17562864221083608

Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report

Ther Adv Neurol Disord. 2022 Mar 29:15:17562864221083608. doi: 10.1177/17562864221083608. eCollection 2022.

Authors

Mona Klara Ros Müller¹, Monika Christ¹, Markus Naumann¹, Antonios Bayas²

Affiliations

¹ Department of Neurology and Clinical Neurophysiology, University Hospital Augsburg, Augsburg, Germany.
² Department of Neurology and Clinical Neurophysiology, University Hospital Augsburg, Stenglinstrasse 2, 86156 Augsburg, Germany.

Abstract

Prolonged-release fampridine (PR-FAM), a potassium channel blocker, is approved for improving walking ability in patients with multiple sclerosis (MS). Beyond this, positive effects on other MS symptoms like fatigue, cognition, and tremor have been described. To our knowledge, a positive effect of PR-FAM on spinal myoclonus has not been described so far. Here, we report a 32-year-old female with myoclonus after cervical myelitis affecting both hands which markedly improved after administration of PR-FAM. Treatments used before such as carbamazepine or levetiracetam had to be withdrawn because of intolerable side effects or lack of efficacy. The positive effect of PR-FAM could be confirmed by transient suspension. PR-FAM may be considered as a treatment option in refractory spinal myoclonus after myelitis in selected cases.

Keywords: case report; multiple sclerosis; myelitis; prolonged-release fampridine; spinal myoclonus.

Publication types

Case Reports